References

1.
Liberati A, Altman D, Tetzlaff J, Mulrow C, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med. 2009;151(4):W65–W94. [PubMed: 19622512]
2.
Smith B, Carson S, Fu R, et al. Drug class review: Disease-modifying drugs for multiple sclerosis Update 1. 2010. [PubMed: 21348046]
3.
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001 Jul;50(1):121–127. [PubMed: 11456302]
4.
Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983 Mar;13(3):227–231. [PubMed: 6847134]
5.
Center for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews, CRD Report Number 4. 2. York, UK: 2001.
6.
Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am. J. Prev. Med. 2001 Apr;20(3 Suppl):21–35. [PubMed: 11306229]
7.
Owens DK, Lohr KN, Atkins D. Grading the strength of a body of evidence when comparing medical interventions, Agency for Healthcare Research and Quality. Methods Guide for Comparative Effectiveness Reviews. Rockville, MD: 2009. [PubMed: 19595577]
8.
Owens DK, Lohr KN, Atkins D, et al. Grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the Effective Health Care Program. J. Clin. Epidemiol. 2010;63(5):513–523. [PubMed: 19595577]
9.
Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. John Wiley & Sons, Inc; 2000.
10.
Lewis S, Clarke M. Forest plots: trying to see the wood and the trees. BMJ. 2001;322(7300):1479–1480. [PMC free article: PMC1120528] [PubMed: 11408310]
11.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. [PMC free article: PMC192859] [PubMed: 12958120]
12.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002;21(11):1539–1558. [PubMed: 12111919]
13.
Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat. Med. 1999;18(20):2693–2708. [PubMed: 10521860]
14.
U.S. Food and Drug Administration: Center for Drug Evaluation and Research. Fingolimod Statistical and Medical Reviews. NDA. 2010 Aug:22–527. 2010.
15.
Khatri B, Barkhof F, Comi G, et al. 24-month efficacy and safety outcomes from the TRANSFORMS extension study of oral fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis [poster]. Presented at: The American Academy of Neurology 62nd Annual Meeting; Toronto, Canada. April 10–17, 2010; 2010.
16.
Cohen J, Montalban X, Pelletier J, et al. Efficacy and safety of fingolimod in patients switched from intramuscular interferon β-1a: results from the TRANSFORMS extension study [poster – P827]. Presented at: The 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; Gothenberg, Sweden. October 13–16, 2010; 2010.
17.
Cohen J, Barkhof F, Comi G, et al. Oral fingolimod (FTY720) treatment improves the performance of daily activities compared with intramuscular interferon β-1a: Patient-Reported Indices for Multiple Sclerosis (PRIMUS)-Activities results from a Phase III study (TRANSFORMS) [poster]. Presented at: The American Academy of Neurology Annual Meeting; Toronto, Canada. April 10–17, 2010; 2010.
18.
Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010 Feb 4;362(5):402–415. [PubMed: 20089954]
19.
Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 2006 Sep 14;355(11):1124–1140. [PubMed: 16971719]
20.
Kappos L, O’Connor P, Polman C, et al. Oral fingolimod (FTY720) vs placebo in relapsing remitting multiple sclerosis: 24 month clinical efficacy results from a randomized, double-blind, multicenter phase III study (FREEDOMS) [presentation]. Presented at: The American Academy of Neurology 62nd Annual Meeting; Toronto, Canada. April 10–17, 2010; 2010.
21.
Kappos L, Radue EW, O’Connor P, et al. Majority of patients with relapsing multiple sclerosis receiving oral fingolimod (FTY720, a sphingosine-1-phosphate receptor modulator) remain free from any inflammatory activity: Results of a 4-year, Phase II extension [presentation]. Presented at: The 19th European Neurological Society; Milan, Italy. June 20–24, 2009; 2009.
22.
Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010 Feb 4;362(5):387–401. [PubMed: 20089952]
23.
Khatri B, Barkhof F, Comi G, et al. Oral fingolimod (FTY720) reduces the rate of relapses that require steroid intervention or hospitalization compared with intramuscular interferon β-1a: results from a phase III study (TRANSFORMS) in multiple sclerosis [poster]. Presented at: The American Academy of Neurology 62nd Annual Meeting; Toronto, Canada. April 10–17, 2010; 2010.
24.
O’Connor P, Polman C, Hohlfeld R, et al. Oral fingolimod (FTY720) vs placebo in relapsing remitting multiple sclerosis: 24 month safety and tolerability results from a randomized, double-blind, multicenter phase III study (FREEDOMS) [poster - P06171]. Presented at: The American Academy of Neurology 62nd Annual Meeting; Toronto, Canada. April 10–17, 2010; 2010.
25.
O’Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology. 2009 Jan 6;72(1):73–79. [PubMed: 19122034]
26.
von Rosenstiel P, Hohlfeld R, Calabresi P, et al. Clinical Outcomes in subgroups of patients treated with fingolimod (FTY720) or placebo: 24 month results from FREEDOMS [poster-P434]. Presented at: The 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; Vol Gothenberg, Sweden. October 13–16, 2010; 2010.
27.
Kappos L, Comi G, Montalban X, et al. Oral FTY720 (fingolimod) in relapsing multiple sclerosis: impact on patient-reported depression, as measured by the Beck Depression Inventory II in a 6-month, placebo-controlled study. Neurology. 2007;68:A276.